My career as an academic hematopathologist has focused heavily on not only the morphologic appearance of hemaotlymphoid diseases but also on their chemistry and molecular findings. I have a long and successful record of demonstrating such changes and how they impact response to treatment and prognosis. Not only have I interpreted and integrated morphology, immunohistochemistry and molecular changes in hematolymphoid malignancies such as malignant lymphoma, I have also shown their clinical relevance. This has occurred both as part of a large, mulitinstitutional grou(Southwest Oncology Group) and independent of it. I work independently in developing test results but am also a team player in working with many researchers in getting a question from concept through design and to completion of published results. Thus, I am confident in my ability to advance all projects of which I am a part. I have clinical responsibilities in two main areas: hematopathology and HLA. The Hematopathology includes responsibility for the proper diagnosis of various hematologic and lymphoid disorders that occur in the blood, bone marrow, lymph nodes or other sites. Modalities used include morphologic interpretation, flow cytometry, immunohistochemistry and cytogenetic/molecular tests. I also have rspoonsibility for the evaluation and diagnosis of disorders that are seen in body fluids and urine. As the Chief of the Hematopathology section, I also have administrative oversight for hematology, bone marrows, body fluids and urines that includes proper instrumentation and technical staff. skilled for proper running of instruments and trouble shooting. In addition, I am required to have this laboratory remain accredited so that good patient care occurs. Regarding the HLA Laboratory, I am both its Medical Director and the one pathologist who signs out all cases. This is a busy laboratory with responsibility for proper testing for all transplants that occur at BUMCT liver transplants do not require any input from the HLA laboratory) The timecovered is from when a person is first identified as a potential transplant recipient for as long as they are under the care of a physician at BUMCT. Not only does this include their HLA typing, it also includes testing for any anit-HLA antibody(ies) that may develop, their precise identification and monitoring. All crossmatches for organ transplant are also performed in this laboratory. Patients who are potential transplant recipients include those who need a kidney, pancreas, kidneyancreas, heart, lung, or bone marrow. Potential donors kidney and bone marrow) may also be evaluated in this laboratory, including unrelated donors. As well as patient care, I have the responsibility for the correct technical running of the laboratory as well as its accreditation. The accreditation is through both the CAP as well as the more specialized ASHI American Society for Histocompatibility and Immunogenetics) organization. The HLA laboratory is required to be ASHI accredited by UNOS United Network for Organ Sharing) which is the organization that allows a hospital to be able to have transplant patients. I am also currently the mentor for a new HLA Laboratory Director in training. This requires education of the mentee through all aspects of the HLA laboratory, in preparation for the examination given by the ABHI, the accrediting organization for HLA Laboratory Directors. This is a rigorous educational experience with near-daily interactions and teaching. It is a 4 year timefrom beginning to exam. I am also involved in the teaching of medical students, pathology residents, Hematopathology Fellow and other learners who may have a rotation in the laboratory. This teaching rests primarily in Hematology when we sign out diagnostic cases. In addition, I teach Nephrology Fellows and pathology residents when they have a rotation in the HLA laboratory. I also give a formal lecture to the Nephrology Fellows on the basics of HLA and its impact on renal transplant and followup.